

11-591-C025

Monoclonal Antibody to CD334 / FGFR4 Purified Antibody (0.025 mg)

Clone:	4FR6D3
Isotype:	Mouse IgG1
Specificity:	The mouse monoclonal antibody 4FR6D3 reacts with CD334, the fibroblast growth factor receptor 4, which is an approximately 88 kDa receptor tyrosine kinase expressed in variety of tissues.
Regulatory Status:	RUO
Immunogen:	NIH 3T3 cells transfected with full length human CD334
Species Reactivity:	Human
Application:	Flow Cytometry Immunocytochemistry
Purity:	> 95% (by SDS-PAGE)
Purification:	Purified by protein-A affinity chromatography
Concentration:	1 mg/ml
Storage Buffer:	Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4
Storage / Stability:	Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Expiration:	See vial label
Lot Number:	See vial label
Background:	CD334 / FGFR4 (fibroblast growth factor receptor 4), a transmembrane tyrosine kinase, which is expressed in many tissues, such as in lung, kidney, muscle, heart, pancreas, intestine and other, acts as a receptor for several fibroblast growth factors, namely FGF1, FGF2, FGF6, FGF8, and FGF19. Interaction with these growth factors initiates in cell the signaling cascades leading to the mitogenesis and cell differentiation. Presence of CD334 Gly338Arg allele correlates with prognostic parameters in various cancer studies. CD334 plays multiple roles in the organism, including those of muscle regeneration, cholesterol-to-bile acid metabolism, or glucose homeostasis.

For laboratory research only, not for drug, diagnostic or other use.

**Antibodies****References:**

- *Partanen J, Mäkelä TP, Eerola E, Korhonen J, Hirvonen H, Claesson-Welsh L, Alitalo K: FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern. *EMBO J.* 1991 Jun;10(6):1347-54.
- *Vainikka S, Partanen J, Bellosta P, Coulier F, Birnbaum D, Basilico C, Jaye M, Alitalo K: Fibroblast growth factor receptor-4 shows novel features in genomic structure, ligand binding and signal transduction. *EMBO J.* 1992 Dec;11(12):4273-80.
- *Bange J, Prechtel D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, Knyazeva T, Müller S, Gärtner S, Sures I, Wang H, Imyanitov E, Häring HU, Knayzev P, Iacobelli S, Höfler H, Ullrich A: Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. *Cancer Res.* 2002 Feb 1;62(3):840-7.
- *Yang YC, Lu ML, Rao JY, Wallerand H, Cai L, Cao W, Pantuck A, Dalbagni G, Reuter V, Figlin RA, Beldegrun A, Cordon-Cardo C, Zhang ZF: Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis. *Br J Cancer.* 2006 Dec 4;95(11):1455-8.
- *Zhao P, Caretti G, Mitchell S, McKeegan WL, Boskey AL, Pachman LM, Sartorelli V, Hoffman EP: Fgfr4 is required for effective muscle regeneration in vivo. Delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway. *J Biol Chem.* 2006 Jan 6;281(1):429-38.
- *Huang X, Yang C, Luo Y, Jin C, Wang F, McKeegan WL: FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. *Diabetes.* 2007 Oct;56(10):2501-10.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.

For laboratory research only, not for drug, diagnostic or other use.

EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic
Tel: +420 261 090 666 | Fax: +420 261 090 660 | orders@exbio.cz | www.exbio.cz